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by BMJ. Figure 1 (A) Tense blisters as well as eczematous 
lesions on the thigh. (B) Subepidermal blister with 
inflammatory contents and eosinophils. There is a 
perivascular and interstitial inflammatory component of 
lymphocytes and eosinophils in the superficial dermis 
(HEx10). (C) The direct immunofluorescence study shows 
linear immunoglobulin G deposits in the epidermal 
basement membrane. (D) C3 deposits are also seen.
A 97- year- old man with a history of type II diabetes 
mellitus was treated with oral antidiabetic agents. 
He went to the emergency department after the 
appearance of blister- like itchy lesions on the 
abdomen and extremities since 2 months.
The examination revealed eczematous lesions on 
the back, abdomen and extremities along with tense 
blisters on an erythematous base and serous content 
(figure 1A).
In the blood test carried out, 285 mg/dL glucose 
and 7.1% eosinophilia stood out, with no associ-
ated leucocytosis or other relevant findings. Posi-
tive glycosuria (+++) was observed in urinalysis 
without other alterations.
A skin biopsy was performed for histological and 
immunofluorescence studies that confirmed the 
diagnosis of bullous pemphigoid (figure 1B–D).
Given the poor control of autoimmune blistering 
disease, possible triggers were looked for and lina-
gliptin intake could be associated with the appear-
ance of skin lesions 1 month earlier.
Linagliptin was replaced by metformin and the 
oral corticoid regimen was continued, along with 
high- power topical corticosteroids (clobetasol 
propionate), allowing a good therapeutic response.
The increase in the prevalence of type II diabetes 
mellitus in the population and the expanded use of 
oral antidiabetic agents, such as dipeptidyl pepti-
dase-4 inhibitors (DPP4is), has led to the appear-
ance of adverse effects which were unknown for 
some time.
Among these adverse effects is the occurrence of 
bullous pemphigoid, with an increased incidence 
in recent years.1 This pathology is caused by anti-
bodies directed against proteins of the hemides-
mosomes of basal keratinocytes of the epidermis. 
Anti- BP180 autoantibodies are known to play an 
important role in the pathogenesis of this autoim-
mune disease; however, little is known about the 
causes of the lack of immune tolerance to BP180 
antigen in certain individuals after taking DPP4is.1
However, one proven fact is the increased inci-
dence of bullous pemphigoid in relation to DPP4is 
treatment in patients with diabetes, with incidence 
rates of 21.1 cases (95% CI 17.9 to 24.8) per 
100 000 person years.2 The first reported case of 
bullous pemphigoid induced by DPP4is dates back 
to 2011,3 and the scientific evidence regarding the 
induction of bullous pemphigoid by this family of 
oral antidiabetic agents has been increasing since 
the first French and European pharmacovigilance 
studies that show an excessively high incidence 
of bullous pemphigoid.4 Since then, an overall 
increase in bullous pemphigoid risk has been noted 
in patients treated with gliptins in several studies.1
Risk estimation studies associated with treat-
ment with gliptins have recently been carried out, 
finding a significant increase in the risk of devel-
oping bullous pemphigoid (OR 1.58, 95% CI 1.25 
to 2.00). The DPP4is with the greatest risk of 
developing bullous pemphigoid is vildagliptin (OR 
1.8, 95% CI 1.31 to 2.50), followed by sitagliptin 
(OR 1.70, 95% CI 1.19 to 2.43) and linagliptin 
(OR 1.64, 95% CI 1.15 to 2.33). The increased 
risk is greater in males (OR 1.91, 95% CI 1.39 
to 2.63) than in females (OR 1.24, 95% CI 0.88 
to 1.75).5 DPP4is- associated bullous pemphigoid 
also has a higher mucosal involvement (22.2% of 
patients) compared with cases not associated with 
these antidiabetics (6.5% of patients).6 DPP4is 
may be replaced by other oral antidiabetics, such 
as metformin, sulfonylureas, thiazolidinediones or 
meglitinides, as they have not been shown to be 
inducers of bullous pemphigoid.7
The studies published in the literature show 
20- month latency times on average (HR 3.60, 95% 
CI 2.11 to 6.16) after the start of DPP4is usage.2 
These long times between the introduction of the 
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drug and the appearance of the skin manifestations make it diffi-
cult to identify the drug as a causal agent. However, its with-
drawal induces rapid remission of the disease within as little as 
10 days (Q1–Q3: 5–15 days) on average.4
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